Clinical trials: Proton Therapy
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Duodenal Ulcer
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and dose-ranging trial.
- Trial name
- NCT00953381
- Testing
- 5 mg ilaprazole, 10 mg ilaprazole, 20 mg ilaprazole
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
The primary objective of this study to examine the long-term safety of rabeprazole 5 mg or 10 mg tablets administered once daily in participants who were confirmed to have no recurrence of gastric or duodenal ulcer by endoscopic…
- Trial name
- NCT01398410
- Testing
- Rabeprazole
- Where
- 50 sites in Japan
- Volunteers
- 405 people
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux
Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment
The primary objective of the study is to describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(using GerdQ questionnaire).
- Trial name
- NCT01103804
- Where
- 19 sites in Romania
- Volunteers
- 952 people
- Sponsor
- AstraZeneca
Healthy
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.
This study will estimate the effect of food and the proton pump inhibitor, esomeprazole on the pharmacokinetics of crizotinib in a coated microsphere formulation.
- Trial name
- NCT03137134
- Testing
- Crizotinib, Esomeprazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gastroesophageal Reflux Disease (GERD)
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI…
- Trial name
- REMAIN (NCT00795093)
- Where
- 53 sites in United States
- Volunteers
- 552 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD), Peptic Ulcers
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00261300
- Testing
- Pantoprazole
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Takeda
Healthy Volunteers
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
The primary objective of the study is to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally in healthy volunteers.
- Trial name
- NCT05497557
- Testing
- Omeprazole, Sotorasib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Amgen
Death, Sudden, Cardiac
An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
The purpose of this observational study is to assess the risk of out-of-hospital Sudden Cardiac (heart) Death (SCD) associated with current use of domperidone compared to current use of a Proton Pump Inhibitor (PPI), current use…
- Trial name
- NCT01907633
- Testing
- No intervention
- Volunteers
- 15,000 people
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
The main purpose of this study is to learn about how food and a PPI (omeprazole) affect LOXO-305 in healthy participants. Participation could last about nine weeks.
- Trial name
- NCT05134350
- Testing
- LOXO-305, Omeprazole
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
Healthy
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)
The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
- Trial name
- NCT06619314
- Testing
- Calderasib, PPI
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects
Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan
This study is designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.
- Trial name
- NCT07054593
- Testing
- CapScan
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Envivo Bio Inc
Healthy
Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Comparison of pharmacokinetics of dipyridamole administered as Aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.
- Trial name
- NCT02251184
- Testing
- Aggrenox, Dipyridamole, Aspirin
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Psoriasis
Proton Pump Inhibitors Use in Patients With Psoriasis
Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients…
- Trial name
- NCT02624544
- Testing
- esomeprazole, desonide
- Sponsor
- EMS
Healthy Volunteers
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.
- Trial name
- NCT07329972
- Testing
- ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Participants
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
The purpose of this study is to compare multiple formulations of PF-07220060 in terms of their uptake into the blood stream. The study will assess the effects of food and Rabeprazole on the uptake of PF-07220060.
- Trial name
- NCT05923411
- Testing
- Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dyspepsia, H. Pylori Infection
Supplementation With L. Reuteri in H. Pylori Infected Adults
To determine whether simultaneous use of L. reuteri ProGastria and proton pump inhibitors can eradicate H. pylori in humans in the absence of antibiotics.
- Trial name
- NCT01449500
- Testing
- L. reuteri
- Where
- Slovakia
- Volunteers
- 56 people
- Sponsor
- Lama Medical Care s.r.o.
Helicobacter Pylori Infection
10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Helicobacter pylori (H. pylori) infection is highly associated with gastrointestinal disorders, including peptic ulcer disease, gastric cancer, and gastric mucosa associated lymphoid tissue lymphoma.1 In 1994, H.
- Trial name
- NCT02959255
- Testing
- Esomeprazole
- Where
- Greece
- Volunteers
- 364 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a…
- Trial name
- NCT01397448
- Testing
- E3810, Teprenone
- Where
- 49 sites in Japan
- Volunteers
- 472 people
- Sponsor
- Eisai Co., Ltd.